Emma A Webb1,2,3, Meena Balasubramanian4, Nadja Fratzl-Zelman5, Wayne A Cabral6, Hannah Titheradge7, Atif Alsaedi7, Vrinda Saraff1, Julie Vogt7, Trevor Cole7, Susan Stewart7, Nicola J Crabtree1, Brandi M Sargent6, Sonja Gamsjaeger5, Eleftherios P Paschalis5, Paul Roschger5, Klaus Klaushofer5, Nick J Shaw1,2,3, Joan C Marini6, Wolfgang Högler1,2,3. 1. Department of Endocrinology and Diabetes, Birmingham Children's Hospital, Birmingham B4 6NH, United Kingdom. 2. Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, United Kingdom. 3. Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham B15 2TH, United Kingdom. 4. Sheffield Clinical Genetics Service, Sheffield Children's National Health Service Foundation Trust, Sheffield S10 2TH United Kingdom. 5. Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of Wiener Gebietskrankenkasse and Allgemeine Unfallversicherungsanstalt Trama Centre Meidling, First Medical Department, Hanusch Hospital, 1140 Vienna, Austria. 6. Section on Heritable Disorders of Bone and Extracellular Matrix, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892. 7. Department of Clinical Genetics, Birmingham Women's Hospital, Birmingham B15 2DG, United Kingdom.
Abstract
Context: Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI) by dysregulating intracellular calcium flux. Objectives: Clinical and bone material phenotype description and osteoblast differentiation studies. Design and Setting: Natural history study in pediatric research centers. Patients: Eight patients with type XIV OI. Main Outcome Measures: Clinical examinations included bone mineral density, radiographs, echocardiography, and muscle biopsy. Bone biopsy samples (n = 3) were analyzed using histomorphometry, quantitative backscattered electron microscopy, and Raman microspectroscopy. Cellular differentiation studies were performed on proband and control osteoblasts and normal murine osteoclasts. Results: Type XIV OI clinical phenotype ranges from asymptomatic to severe. Previously unreported features include vertebral fractures, periosteal cloaking, coxa vara, and extraskeletal features (muscular hypotonia, cardiac abnormalities). Proband lumbar spine bone density z score was reduced [median -3.3 (range -4.77 to +0.1; n = 7)] and increased by +1.7 (1.17 to 3.0; n = 3) following bisphosphonate therapy. TMEM38B mutant bone has reduced trabecular bone volume, osteoblast, and particularly osteoclast numbers, with >80% reduction in bone resorption. Bone matrix mineralization is normal and nanoporosity low. We demonstrate a complex osteoblast differentiation defect with decreased expression of early markers and increased expression of late and mineralization-related markers. Predominance of trimeric intracellular cation channel type B over type A expression in murine osteoclasts supports an intrinsic osteoclast defect underlying low bone turnover. Conclusions: OI type XIV has a bone histology, matrix mineralization, and osteoblast differentiation pattern that is distinct from OI with collagen defects. Probands are responsive to bisphosphonates and some show muscular and cardiovascular features possibly related to intracellular calcium flux abnormalities.
Context: Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI) by dysregulating intracellular calcium flux. Objectives: Clinical and bone material phenotype description and osteoblast differentiation studies. Design and Setting: Natural history study in pediatric research centers. Patients: Eight patients with type XIV OI. Main Outcome Measures: Clinical examinations included bone mineral density, radiographs, echocardiography, and muscle biopsy. Bone biopsy samples (n = 3) were analyzed using histomorphometry, quantitative backscattered electron microscopy, and Raman microspectroscopy. Cellular differentiation studies were performed on proband and control osteoblasts and normal murine osteoclasts. Results: Type XIV OI clinical phenotype ranges from asymptomatic to severe. Previously unreported features include vertebral fractures, periosteal cloaking, coxa vara, and extraskeletal features (muscular hypotonia, cardiac abnormalities). Proband lumbar spine bone density z score was reduced [median -3.3 (range -4.77 to +0.1; n = 7)] and increased by +1.7 (1.17 to 3.0; n = 3) following bisphosphonate therapy. TMEM38B mutant bone has reduced trabecular bone volume, osteoblast, and particularly osteoclast numbers, with >80% reduction in bone resorption. Bone matrix mineralization is normal and nanoporosity low. We demonstrate a complex osteoblast differentiation defect with decreased expression of early markers and increased expression of late and mineralization-related markers. Predominance of trimeric intracellular cation channel type B over type A expression in murine osteoclasts supports an intrinsic osteoclast defect underlying low bone turnover. Conclusions: OI type XIV has a bone histology, matrix mineralization, and osteoblast differentiation pattern that is distinct from OI with collagen defects. Probands are responsive to bisphosphonates and some show muscular and cardiovascular features possibly related to intracellular calciumflux abnormalities.
Authors: Xinyu Zhou; Peihui Lin; Daiju Yamazaki; Ki Ho Park; Shinji Komazaki; S R Wayne Chen; Hiroshi Takeshima; Jianjie Ma Journal: Circ Res Date: 2014-02-14 Impact factor: 17.367
Authors: Eleftherios P Paschalis; Sonja Gamsjaeger; Nadja Fratzl-Zelman; Paul Roschger; Admir Masic; Wolfgang Brozek; Norbert Hassler; Francis H Glorieux; Frank Rauch; Klaus Klaushofer; Peter Fratzl Journal: J Bone Miner Res Date: 2016-02-11 Impact factor: 6.741
Authors: Matthew L Warman; Valerie Cormier-Daire; Christine Hall; Deborah Krakow; Ralph Lachman; Martine LeMerrer; Geert Mortier; Stefan Mundlos; Gen Nishimura; David L Rimoin; Stephen Robertson; Ravi Savarirayan; David Sillence; Juergen Spranger; Sheila Unger; Bernhard Zabel; Andrea Superti-Furga Journal: Am J Med Genet A Date: 2011-03-15 Impact factor: 2.802
Authors: Sanne Treurniet; Elisabeth M W Eekhoff; Felix N Schmidt; Dimitra Micha; Björn Busse; Nathalie Bravenboer Journal: Front Endocrinol (Lausanne) Date: 2020-06-23 Impact factor: 5.555
Authors: Laura Leoni; Francesca Tonelli; Roberta Besio; Roberta Gioia; Francesco Moccia; Antonio Rossi; Antonella Forlino Journal: PLoS One Date: 2021-09-28 Impact factor: 3.240